{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,4,14]],"date-time":"2026-04-14T07:53:49Z","timestamp":1776153229493,"version":"3.50.1"},"reference-count":37,"publisher":"Elsevier BV","issue":"3","license":[{"start":{"date-parts":[[2026,4,1]],"date-time":"2026-04-01T00:00:00Z","timestamp":1775001600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2026,4,1]],"date-time":"2026-04-01T00:00:00Z","timestamp":1775001600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2026,2,3]],"date-time":"2026-02-03T00:00:00Z","timestamp":1770076800000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"funder":[{"DOI":"10.13039\/100015676","name":"NSW Health Pathology","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100015676","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["clinicalkey.com","clinicalkey.com.au","clinicalkey.es","clinicalkey.fr","clinicalkey.jp","pathologyjournal.rcpa.edu.au","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Pathology"],"published-print":{"date-parts":[[2026,4]]},"DOI":"10.1016\/j.pathol.2025.11.010","type":"journal-article","created":{"date-parts":[[2026,2,6]],"date-time":"2026-02-06T00:28:34Z","timestamp":1770337714000},"page":"335-340","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":0,"title":["In vitro activity of recently introduced Gram-positive-specific antimicrobial agents against Australian methicillin-resistant Staphylococcus aureus isolates"],"prefix":"10.1016","volume":"58","author":[{"given":"Rebecca","family":"Sparks","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Andrew N.","family":"Ginn","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Elena","family":"Martinez","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Menuk","family":"Jayawardena","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Jenny","family":"Draper","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Qinning","family":"Wang","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-8783-5323","authenticated-orcid":false,"given":"Matthew V.N.","family":"O'Sullivan","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Jonathan R.","family":"Iredell","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-9457-8262","authenticated-orcid":false,"given":"Indy","family":"Sandaradura","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"78","reference":[{"key":"10.1016\/j.pathol.2025.11.010_bib1","doi-asserted-by":"crossref","first-page":"1076","DOI":"10.1016\/j.cmi.2022.03.015","article-title":"Staphylococcus aureus bacteraemia mortality: a systematic review and meta-analysis","volume":"28","author":"Bai","year":"2022","journal-title":"Clin Microbiol Infect"},{"key":"10.1016\/j.pathol.2025.11.010_bib2","series-title":"Australian group on antimicrobial resistance surveillance outcomes programs. Bloodstream infections: 2023 report","author":"Coombs","year":"2024"},{"key":"10.1016\/j.pathol.2025.11.010_bib3","doi-asserted-by":"crossref","first-page":"236","DOI":"10.1186\/1756-0500-4-236","article-title":"The study of vancomycin use and its adverse reactions associated to patients of a Brazilian university hospital","volume":"4","author":"Marinho","year":"2011","journal-title":"BMC Res Notes"},{"key":"10.1016\/j.pathol.2025.11.010_bib4","doi-asserted-by":"crossref","first-page":"23","DOI":"10.1016\/j.jgar.2013.01.002","article-title":"Vancomycin in the treatment of meticillin-resistant Staphylococcus aureus (MRSA) infection: end of an era?","volume":"1","author":"Bal","year":"2013","journal-title":"J Glob Antimicrob Resist"},{"key":"10.1016\/j.pathol.2025.11.010_bib5","doi-asserted-by":"crossref","first-page":"653","DOI":"10.1056\/NEJMoa053783","article-title":"Daptomycin versus standard therapy for bacteremia and endocarditis caused by Staphylococcus aureus","volume":"355","author":"Fowler","year":"2006","journal-title":"N Engl J Med"},{"key":"10.1016\/j.pathol.2025.11.010_bib6","doi-asserted-by":"crossref","first-page":"295","DOI":"10.1016\/j.jgar.2017.05.019","article-title":"Future trends in the treatment of methicillin-resistant Staphylococcus aureus (MRSA) infection: an in-depth review of newer antibiotics active against an enduring pathogen","volume":"10","author":"Bal","year":"2017","journal-title":"J Glob Antimicrob Resist"},{"key":"10.1016\/j.pathol.2025.11.010_bib7","doi-asserted-by":"crossref","first-page":"7837","DOI":"10.1128\/AAC.02015-15","article-title":"Reduced in vitro activity of ceftaroline by Etest among clonal complex 239 methicillin-resistant Staphylococcus aureus clinical strains from Australia","volume":"59","author":"Abbott","year":"2015","journal-title":"Antimicrob Agents Chemother"},{"key":"10.1016\/j.pathol.2025.11.010_bib8","doi-asserted-by":"crossref","DOI":"10.1371\/journal.pone.0125864","article-title":"Pre-use susceptibility to ceftaroline in clinical Staphylococcus aureus isolates from Germany: is there a non-susceptible pool to be selected?","volume":"10","author":"Strommenger","year":"2015","journal-title":"PLoS One"},{"key":"10.1016\/j.pathol.2025.11.010_bib9","doi-asserted-by":"crossref","first-page":"3453","DOI":"10.1093\/jac\/dkz371","article-title":"Staphylococcus aureus from hospital-acquired pneumonia from an Italian nationwide survey: activity of ceftobiprole and other anti-staphylococcal agents, and molecular epidemiology of methicillin-resistant isolates","volume":"74","author":"Antonelli","year":"2019","journal-title":"J Antimicrob Chemother"},{"key":"10.1016\/j.pathol.2025.11.010_bib10","doi-asserted-by":"crossref","DOI":"10.1128\/AAC.02158-18","article-title":"Low prevalence of Gram-positive isolates showing elevated lefamulin MIC results during the SENTRY surveillance program for 2015\u20132016 and characterization of resistance mechanisms","volume":"63","author":"Mendes","year":"2019","journal-title":"Antimicrob Agents Chemother"},{"key":"10.1016\/j.pathol.2025.11.010_bib11","series-title":"AURA 2023: Fifth Australian report on antimicrobial use and resistance in human health","year":"2023"},{"key":"10.1016\/j.pathol.2025.11.010_bib12","series-title":"Methods for dilution antimicrobial susceptibility tests for bacteria that grow aerobically","year":"2018"},{"key":"10.1016\/j.pathol.2025.11.010_bib13","series-title":"European Committee on Antimicrobial Susceptibility Testing. Breakpoint tables for interpretation of MICs and zone diameters. Version 14.0","year":"2024"},{"key":"10.1016\/j.pathol.2025.11.010_bib14","doi-asserted-by":"crossref","first-page":"37","DOI":"10.1186\/s12941-022-00529-z","article-title":"Antibacterial activity of recently approved antibiotics against methicillin-resistant Staphylococcus aureus (MRSA) strains: a systematic review and meta-analysis","volume":"21","author":"Liu","year":"2022","journal-title":"Ann Clin Microbiol Antimicrob"},{"key":"10.1016\/j.pathol.2025.11.010_bib15","doi-asserted-by":"crossref","first-page":"323","DOI":"10.1016\/j.ijantimicag.2013.11.005","article-title":"Activity of ceftobiprole against methicillin-resistant Staphylococcus aureus strains with reduced susceptibility to daptomycin, linezolid or vancomycin, and strains with defined SCCmec types","volume":"43","author":"Farrell","year":"2014","journal-title":"Int J Antimicrob Agents"},{"key":"10.1016\/j.pathol.2025.11.010_bib16","doi-asserted-by":"crossref","first-page":"1933","DOI":"10.1007\/s10096-016-2744-3","article-title":"In vitro activity of tedizolid against Staphylococcus aureus and Streptococcus pneumoniae collected in 2013 and 2014 from sites in Latin American countries, Australia, New Zealand, and China","volume":"35","author":"Biedenbach","year":"2016","journal-title":"Eur J Clin Microbiol Infect Dis"},{"key":"10.1016\/j.pathol.2025.11.010_bib17","doi-asserted-by":"crossref","first-page":"5393","DOI":"10.1128\/AAC.00881-16","article-title":"Activities of tedizolid and linezolid determined by the reference broth microdilution method against 3,032 Gram-positive bacterial isolates collected in Asia-Pacific, Eastern Europe, and Latin American countries in 2014","volume":"60","author":"Pfaller","year":"2016","journal-title":"Antimicrob Agents Chemother"},{"key":"10.1016\/j.pathol.2025.11.010_bib18","doi-asserted-by":"crossref","first-page":"151","DOI":"10.1016\/j.diagmicrobio.2017.07.001","article-title":"In vitro activities of tedizolid and comparator antimicrobial agents against clinical isolates of Staphylococcus aureus collected in 12 countries from 2014 to 2016","volume":"89","author":"Karlowsky","year":"2017","journal-title":"Diagn Microbiol Infect Dis"},{"key":"10.1016\/j.pathol.2025.11.010_bib19","article-title":"In vitro activity of eravacycline against Gram-positive bacteria isolated in clinical laboratories worldwide from 2013 to 2017","volume":"64","author":"Morrissey","year":"2020","journal-title":"Antimicrob Agents Chemother"},{"key":"10.1016\/j.pathol.2025.11.010_bib20","doi-asserted-by":"crossref","first-page":"61","DOI":"10.1016\/j.diagmicrobio.2013.01.005","article-title":"Antimicrobial activity of ceftaroline and comparator agents tested against bacterial isolates causing skin and soft tissue infections and community-acquired respiratory tract infections isolated from the Asia-Pacific region and South Africa (2010)","volume":"76","author":"Sader","year":"2013","journal-title":"Diagn Microbiol Infect Dis"},{"key":"10.1016\/j.pathol.2025.11.010_bib21","doi-asserted-by":"crossref","first-page":"149","DOI":"10.1016\/j.jgar.2013.04.005","volume":"1","author":"Coombs","year":"2013","journal-title":"J Glob Antimicrob Resist"},{"key":"10.1016\/j.pathol.2025.11.010_bib22","doi-asserted-by":"crossref","first-page":"71","DOI":"10.1097\/PAT.0000000000000032","article-title":"Activity of ceftaroline against community associated and healthcare associated methicillin resistant Staphylococcus aureus","volume":"46","author":"Coombs","year":"2014","journal-title":"Pathology"},{"key":"10.1016\/j.pathol.2025.11.010_bib23","doi-asserted-by":"crossref","first-page":"183","DOI":"10.1016\/j.jgar.2014.02.006","article-title":"In vitro activity of ceftaroline tested against isolates from the Asia-Pacific region and South Africa (2011)","volume":"2","author":"Flamm","year":"2014","journal-title":"J Glob Antimicrob Resist"},{"key":"10.1016\/j.pathol.2025.11.010_bib24","doi-asserted-by":"crossref","first-page":"797","DOI":"10.1093\/jac\/dku455","article-title":"Ceftaroline fosamil salvage therapy: an option for reduced-vancomycin-susceptible MRSA bacteraemia","volume":"70","author":"Espedido","year":"2015","journal-title":"J Antimicrob Chemother"},{"key":"10.1016\/j.pathol.2025.11.010_bib25","doi-asserted-by":"crossref","first-page":"2413","DOI":"10.1093\/jac\/dkv124","article-title":"Non-susceptibility to ceftaroline in healthcare-associated multiresistant MRSA in Eastern Australia","volume":"70","author":"Mubarak","year":"2015","journal-title":"J Antimicrob Chemother"},{"key":"10.1016\/j.pathol.2025.11.010_bib26","doi-asserted-by":"crossref","first-page":"343","DOI":"10.1128\/AAC.01867-15","article-title":"In vitro activity of ceftaroline against Staphylococcus aureus isolated in 2012 from Asia-Pacific countries as part of the AWARE surveillance program","volume":"60","author":"Biedenbach","year":"2016","journal-title":"Antimicrob Agents Chemother"},{"key":"10.1016\/j.pathol.2025.11.010_bib27","doi-asserted-by":"crossref","first-page":"103","DOI":"10.1016\/j.jgar.2018.11.013","article-title":"Frequency and antimicrobial susceptibility of bacterial isolates from patients hospitalised with community-acquired skin and skin-structure infection in Europe, Asia and Latin America","volume":"17","author":"Sader","year":"2019","journal-title":"J Glob Antimicrob Resist"},{"key":"10.1016\/j.pathol.2025.11.010_bib28","doi-asserted-by":"crossref","first-page":"82","DOI":"10.1016\/j.ijid.2018.10.004","article-title":"Antimicrobial activity of ceftaroline and comparator agents tested against organisms isolated from patients with community-acquired bacterial pneumonia in Europe, Asia, and Latin America","volume":"77","author":"Sader","year":"2018","journal-title":"Int J Infect Dis"},{"key":"10.1016\/j.pathol.2025.11.010_bib29","doi-asserted-by":"crossref","first-page":"524","DOI":"10.1016\/j.ijid.2020.11.130","article-title":"Ceftaroline activity against Staphylococcus aureus isolated from patients with infective endocarditis, worldwide (2010\u20132019)","volume":"102","author":"Sader","year":"2021","journal-title":"Int J Infect Dis"},{"key":"10.1016\/j.pathol.2025.11.010_bib30","doi-asserted-by":"crossref","DOI":"10.1128\/AAC.00018-17","article-title":"Surveillance of omadacycline activity against clinical isolates from a global collection (North America, Europe, Latin America, Asia-Western Pacific), 2010\u20132011","volume":"61","author":"Pfaller","year":"2017","journal-title":"Antimicrob Agents Chemother"},{"key":"10.1016\/j.pathol.2025.11.010_bib31","series-title":"Omadacycline injection and oral products","year":"2020"},{"key":"10.1016\/j.pathol.2025.11.010_bib32","doi-asserted-by":"crossref","DOI":"10.1128\/AAC.02161-18","article-title":"Antibacterial activity of lefamulin against pathogens most commonly causing community-acquired bacterial pneumonia: SENTRY Antimicrobial Surveillance Program (2015\u20132016)","volume":"63","author":"Paukner","year":"2019","journal-title":"Antimicrob Agents Chemother"},{"key":"10.1016\/j.pathol.2025.11.010_bib33","doi-asserted-by":"crossref","first-page":"2605","DOI":"10.1093\/jac\/dkaa209","article-title":"Delafloxacin activity against Staphylococcus aureus with reduced susceptibility or resistance to methicillin, vancomycin, daptomycin or linezolid","volume":"75","author":"Saravolatz","year":"2020","journal-title":"J Antimicrob Chemother"},{"key":"10.1016\/j.pathol.2025.11.010_bib34","doi-asserted-by":"crossref","DOI":"10.1128\/AAC.00772-17","article-title":"In vitro activity of delafloxacin and microbiological response against fluoroquinolone-susceptible and nonsusceptible Staphylococcus aureus isolates from two phase 3 studies of acute bacterial skin and skin structure infections","volume":"61","author":"McCurdy","year":"2017","journal-title":"Antimicrob Agents Chemother"},{"key":"10.1016\/j.pathol.2025.11.010_bib35","doi-asserted-by":"crossref","first-page":"1758","DOI":"10.1093\/cid\/ciz787","article-title":"Emergence of delafloxacin-resistant Staphylococcus aureus in Brooklyn, New York","volume":"70","author":"Iregui","year":"2020","journal-title":"Clin Infect Dis"},{"key":"10.1016\/j.pathol.2025.11.010_bib36","doi-asserted-by":"crossref","first-page":"2814","DOI":"10.1093\/jac\/dks307","article-title":"Activity of delafloxacin against methicillin-resistant Staphylococcus aureus: resistance selection and characterization","volume":"67","author":"Remy","year":"2012","journal-title":"J Antimicrob Chemother"},{"key":"10.1016\/j.pathol.2025.11.010_bib37","doi-asserted-by":"crossref","DOI":"10.1016\/j.ijantimicag.2023.106795","article-title":"High-level delafloxacin resistance through the combination of two different mechanisms in Staphylococcus aureus","volume":"61","author":"de la Rosa","year":"2023","journal-title":"Int J Antimicrob Agents"}],"container-title":["Pathology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0031302526003934?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0031302526003934?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2026,4,14]],"date-time":"2026-04-14T07:05:42Z","timestamp":1776150342000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0031302526003934"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,4]]},"references-count":37,"journal-issue":{"issue":"3","published-print":{"date-parts":[[2026,4]]}},"alternative-id":["S0031302526003934"],"URL":"https:\/\/doi.org\/10.1016\/j.pathol.2025.11.010","relation":{},"ISSN":["0031-3025"],"issn-type":[{"value":"0031-3025","type":"print"}],"subject":[],"published":{"date-parts":[[2026,4]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"In vitro activity of recently introduced Gram-positive-specific antimicrobial agents against Australian methicillin-resistant Staphylococcus aureus isolates","name":"articletitle","label":"Article Title"},{"value":"Pathology","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.pathol.2025.11.010","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2026 The Author(s). Published by Elsevier B.V. on behalf of Royal College of Pathologists of Australasia.","name":"copyright","label":"Copyright"}]}}